News

GT Biopharma Reports Second Quarter 2023 Financial Results

Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated…

1 year ago

Smart for Life Recaps Significant Events Year-to-Date

Review Includes Interactive Links to Company’s Major AnnouncementsMIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL)…

1 year ago

GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models

Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development…

1 year ago

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral…

1 year ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of…

1 year ago

Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral…

1 year ago

ABVC Corporate Update and CEO’s Letter to Shareholders

FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company…

1 year ago

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

1 year ago

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

1 year ago